ESMO

Fertility Preservation Options for Young Patients With Breast Cancer

October 16th 2024, 1:00pm

Video

An expert discussed options young patients with breast cancer may have to preserve their fertility before starting cancer treatment.

Managing Symptoms, Controlling Disease With Radiation in Kidney Cancer

October 14th 2024, 3:00pm

Video

An expert explained how radiation may be a treatment option for patients with renal cell carcinoma to manage symptoms and control the disease.

Rybrevant Plus Chemotherapy May Improve PFS for Relapsed EGFR Lung Cancer

October 12th 2024, 6:00pm

Video

The drug combined with chemotherapy demonstrated a 60% increase in progression-free survival, suggesting signs of an FDA approval.

High vs Low Dose of Vitamin D May Not Impact Treating mCRC

October 7th 2024, 9:00pm

Video

For patients with metastatic colorectal cancer, adding a higher dose proves just as effective as the standard dose of vitamin D3, despite one exception.

Non-Surgical Options May Maintain Relapse-Free Survival in Rectal Cancer Subset

October 5th 2024, 2:00pm

Article

Distance relapse-free survival was maintained in patients with pMMR locally advanced rectal cancer through non-operative management of the disease.

Perioperative Opdivo Extends Event-Free Survival in Lung Cancer

October 3rd 2024, 1:00pm

Article

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo.

Herceptin, Perjeta Regimen May Be Effective Without Chemo in Breast Cancer

October 2nd 2024, 9:00pm

Article

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma

October 1st 2024, 9:00pm

Article

Keytruda continued to improve survival versus Yervoy in unresectable stage 3 or 4 melanoma in long-term follow-up data.

Fotivda Shows Better Outcomes Than Combo in Metastatic Kidney Cancer

October 1st 2024, 1:00pm

Article

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic kidney cancer.

Anti-PD-L1 Antibody Drug Combo May Improve Outcomes in Advanced Kidney Cancer

September 30th 2024, 9:00pm

Article

Benmelstobart plus anlotinib significantly improved survival versus Sutent in the first-line treatment of advanced renal cell carcinoma.